Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and targ...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1253395/full |
| _version_ | 1797740314395410432 |
|---|---|
| author | Frederik Holm Rothemejer Frederik Holm Rothemejer Nanna Pi Lauritsen Nanna Pi Lauritsen Ole Schmeltz Søgaard Ole Schmeltz Søgaard Martin Tolstrup Martin Tolstrup |
| author_facet | Frederik Holm Rothemejer Frederik Holm Rothemejer Nanna Pi Lauritsen Nanna Pi Lauritsen Ole Schmeltz Søgaard Ole Schmeltz Søgaard Martin Tolstrup Martin Tolstrup |
| author_sort | Frederik Holm Rothemejer |
| collection | DOAJ |
| description | Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and target cell abundance are crucial for the engagement, engraftment, and persistence of CAR T cells. The success of HIV-specific CAR T cells is challenged by limited antigen due to low cell surface expression of viral proteins and the scarcity of chronically infected cells during antiretroviral therapy. Several strategies have been explored to increase the efficacy of CAR T cells by enhancing expansion and persistence of the engineered cells. This review highlights the challenges of designing CAR T cells against HIV and other chronic viral infections. We also discuss potential strategies to enhance CAR T cell expansion and persistence in the setting of low antigen exposure. |
| first_indexed | 2024-03-12T14:10:40Z |
| format | Article |
| id | doaj.art-6390eac607594b96aea5c7a8dbf2e689 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T14:10:40Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6390eac607594b96aea5c7a8dbf2e6892023-08-21T08:45:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-08-011410.3389/fimmu.2023.12533951253395Strategies for enhancing CAR T cell expansion and persistence in HIV infectionFrederik Holm Rothemejer0Frederik Holm Rothemejer1Nanna Pi Lauritsen2Nanna Pi Lauritsen3Ole Schmeltz Søgaard4Ole Schmeltz Søgaard5Martin Tolstrup6Martin Tolstrup7Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkChimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and target cell abundance are crucial for the engagement, engraftment, and persistence of CAR T cells. The success of HIV-specific CAR T cells is challenged by limited antigen due to low cell surface expression of viral proteins and the scarcity of chronically infected cells during antiretroviral therapy. Several strategies have been explored to increase the efficacy of CAR T cells by enhancing expansion and persistence of the engineered cells. This review highlights the challenges of designing CAR T cells against HIV and other chronic viral infections. We also discuss potential strategies to enhance CAR T cell expansion and persistence in the setting of low antigen exposure.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1253395/fullchimeric antigen receptorHIVpersistenceexpansionTCR-engagementCAR T cell persistence |
| spellingShingle | Frederik Holm Rothemejer Frederik Holm Rothemejer Nanna Pi Lauritsen Nanna Pi Lauritsen Ole Schmeltz Søgaard Ole Schmeltz Søgaard Martin Tolstrup Martin Tolstrup Strategies for enhancing CAR T cell expansion and persistence in HIV infection Frontiers in Immunology chimeric antigen receptor HIV persistence expansion TCR-engagement CAR T cell persistence |
| title | Strategies for enhancing CAR T cell expansion and persistence in HIV infection |
| title_full | Strategies for enhancing CAR T cell expansion and persistence in HIV infection |
| title_fullStr | Strategies for enhancing CAR T cell expansion and persistence in HIV infection |
| title_full_unstemmed | Strategies for enhancing CAR T cell expansion and persistence in HIV infection |
| title_short | Strategies for enhancing CAR T cell expansion and persistence in HIV infection |
| title_sort | strategies for enhancing car t cell expansion and persistence in hiv infection |
| topic | chimeric antigen receptor HIV persistence expansion TCR-engagement CAR T cell persistence |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1253395/full |
| work_keys_str_mv | AT frederikholmrothemejer strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT frederikholmrothemejer strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT nannapilauritsen strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT nannapilauritsen strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT oleschmeltzsøgaard strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT oleschmeltzsøgaard strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT martintolstrup strategiesforenhancingcartcellexpansionandpersistenceinhivinfection AT martintolstrup strategiesforenhancingcartcellexpansionandpersistenceinhivinfection |